Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for Cerebral Blood Flow and Lung Perfusion in Cognitively Normal Adults
NCT05386914Phase 1Active, not recruiting
- Sponsor
- University of Missouri
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sirolimus in Alzheimer's disease (AD) (2 arms), sponsored by University of Missouri. Primary endpoint: Change in Cerebral Blood Flow at 4 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05386914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386914.